RoboCT

RoboCT stands as a pioneering force in China’s exoskeleton robotics industry, having achieved the distinction of being the first Chinese company to obtain NMPA registration for neurological rehabilitation exoskeletons. Founded in 2017 by Dr. Wang Tian, the company has accumulated over 620,000 patient treatment sessions, with users collectively walking distances equivalent to circling the Earth twice.

Company Overview

The founding team brings deep expertise from Harbin Institute of Technology and Harbin Engineering University, with over a decade of robotics R&D experience. RoboCT has built its competitive advantage through complete in-house development of core components, achieving 100% domestic production of critical parts. This vertical integration enables the company to maintain key module costs at roughly one-tenth of industry averages while achieving gross margins approximately double the industry norm.

The company holds over 500 patents and has led the formulation of multiple national and industry standards for exoskeleton robots. RoboCT operates R&D and manufacturing facilities in Hangzhou, with a new production base in Wuxi designed to scale consumer-grade product manufacturing.

Core Products

UGO Rehabilitation Exoskeleton

The flagship UGO series serves adult patients (1.5-1.9m height, up to 100kg) with lower limb motor dysfunction resulting from spinal cord injury, stroke, hemiplegia, paraplegia, and other central nervous system conditions. The system incorporates 38 sensors for precise movement tracking and four-joint motors for reliable support. Key features include electric stand-up assistance, cloud-based data management, and touchscreen control for speed and stride adjustment. UGO has obtained NMPA Class II certification, CE marking (2024), and FDA registration.

KidGo Pediatric Exoskeleton

Specifically designed for children (0.8-1.6m, up to 100kg) with cerebral palsy, spinal cord injuries, and neuromuscular diseases, KidGo incorporates gamified rehabilitation training to maintain engagement during repetitive gait exercises. The system has achieved NMPA, CE, and FDA regulatory clearances, making it one of the few globally certified pediatric exoskeletons.

URA Bedside Rehabilitation System

The URA Multi-Position Lower Limb Rehabilitation System addresses post-operative recovery needs, particularly following joint replacement surgeries. It enables lower-limb rehabilitation in sitting and lying positions, addressing joint stiffness and adhesions while promoting circulation. The URA system won the Bronze Award at the 2025 New Material Design Award.

UFU Stand-Assisting Robot

Designed for patients unable to stand or walk normally, UFU assists with daily activities including position transfer, standing training, and basic self-care. Its 360-degree rotation capability adapts to confined indoor spaces.

Technology & Innovation

RoboCT’s technical platform integrates multimodal biosignal fusion algorithms that combine EMG (electromyography), EEG (electroencephalography), spinal cord signals, and motion data to generate dynamic rehabilitation pathways. Clinical validation demonstrates 98.7% intent recognition accuracy, tripling daily service efficiency and improving stroke patients’ gait training effectiveness by 53%.

The company has pioneered integration of brain-computer interface and spinal cord stimulation technologies with exoskeleton therapy. Clinical collaboration with leading institutions including Xuanwu Hospital and Huashan Hospital has produced successful “spinal cord stimulation + exoskeleton” combined treatment cases, with patients achieving independent standing within 14 days and 5-meter independent walking within 28 days post-surgery.

Market Presence

RoboCT’s products serve medical institutions across 40+ countries, with particular market expansion along the Belt and Road regions including Southeast Asia, Middle East, Australia, and Europe following CE certification in late 2024. The company has established partnerships with rehabilitation centers and hospitals through its “Rehabilitation-as-a-Service” (RaaS) business model.

Beyond medical applications, RoboCT has expanded into consumer mobility with its GoGo (powered, 2.3kg/side, 25km range) and EasyGo (passive, ~¥2,500) exoskeleton series targeting elderly mobility support and outdoor recreation markets.

Key Milestones

• 2017: Company founded in Hangzhou
• 2021: First Chinese company to obtain NMPA registration for neurological rehabilitation exoskeletons; received 3 categories and 8 product model approvals
• 2021: Won Red Dot Award, iF Design Award, Golden Pin Design Award
• 2022: Completed Series A+ funding; awarded Zhejiang Provincial Key R&D Project
• 2024: UGO series received CE Mark certification
• 2025: Launched EasyGo consumer exoskeleton series; completed Series B funding
• 2026: CES debut with GoGo powered exoskeleton series

Frequently Asked Questions

What conditions can RoboCT exoskeletons treat?

RoboCT’s medical exoskeletons are indicated for patients with lower limb motor dysfunction caused by central nervous system conditions including spinal cord injury, stroke, hemiplegia, paraplegia, acquired brain injury, cerebral palsy, and other neurological diseases. The KidGo series specifically addresses pediatric patients with similar conditions.

What regulatory approvals do RoboCT products have?

The UGO and KidGo rehabilitation exoskeletons have obtained China’s NMPA Class II medical device certification, EU CE marking, and US FDA registration. RoboCT was the first Chinese exoskeleton company to achieve NMPA registration for neurological rehabilitation applications.

Does RoboCT offer products for home use?

Yes, RoboCT offers household versions of its UGO and KidGo exoskeletons designed for home rehabilitation. Additionally, the company has launched consumer-grade products including the EasyGo passive exoskeleton (approximately ¥2,500) and the GoGo powered exoskeleton for daily mobility assistance.